Advertisement
BIO vs TMO
Which Stock Would AI Choose? Bio-Rad Laboratories (BIO) vs. Thermo Fisher Scientific (TMO) Stock Comparison
Key Takeaways
- BIO and TMO operate in the life sciences sector, with TMO offering broader diversification across instruments, reagents, and services while BIO focuses more narrowly on research and clinical diagnostics tools.
- Recent market activity shows TMO delivering stronger year-to-date returns and consistent revenue growth compared to BIO, which has faced downward revisions in currency-neutral guidance.
- BIO reported Q1 2026 net sales of $592.1 million with mixed results influenced by investment fair-value changes and external disruptions, while TMO posted Q1 revenue of $11.01 billion with solid organic growth.
- Market positioning favors TMO due to its larger scale and stability, though BIO may appeal to investors seeking exposure to specialized diagnostics amid sector volatility.
- Sentiment shifts in recent weeks reflect caution around BIO guidance amid academic and government spending pressures, contrasted with steady execution at TMO ahead of its July earnings release.
- Relative performance highlights trade-offs in growth consistency versus niche focus, with both stocks sensitive to broader healthcare and research funding trends.
Introduction
Investors and traders comparing BIO and TMO often seek clarity on relative positioning within the life sciences industry. These stocks represent companies that supply essential tools and technologies for research, diagnostics, and scientific applications, making them relevant for portfolios focused on healthcare innovation and laboratory infrastructure. The comparison appeals to those evaluating momentum, sector exposure, and operational scale amid evolving market conditions and funding environments. Professional and retail participants alike can use this analysis to assess how each company’s business model responds to recent economic and industry-specific factors.
BIO Overview and Recent Performance
Bio-Rad Laboratories develops and manufactures products for life science research and clinical diagnostics markets, including instruments, reagents, and software. In recent weeks, the stock has exhibited volatility influenced by first-quarter results that showed modest reported sales growth offset by currency-neutral declines and a significant GAAP net loss tied to investment valuations. Guidance updates reflected headwinds from reduced federal academic and government spending, particularly in the Middle East region, leading to a more cautious 2026 outlook. Market sentiment has incorporated these factors alongside ongoing reviews of strategic holdings, contributing to tempered performance relative to broader indices.
TMO Overview and Recent Performance
Thermo Fisher Scientific provides a wide array of scientific instruments, reagents, consumables, and services to pharmaceutical, biotech, academic, and government customers worldwide. Recent market activity has highlighted steady execution, with first-quarter revenue growth supported by broad demand across end markets. The company’s upcoming second-quarter earnings release in July has drawn attention to its ability to maintain margins and organic expansion. Sentiment remains supported by consistent delivery on growth initiatives, positioning the stock favorably amid sector dynamics compared to more specialized peers.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of AI trading bots optimized for prevailing market conditions. Tickeron offers hundreds of AI Trading Bots capable of trading thousands of different tickers across varied strategies, timeframes, and performance profiles. Only those demonstrating the strongest alignment with current trends, risk parameters, and statistical robustness earn placement in this section. Available bots feature diverse trading styles, historical win rates, drawdown metrics, and ticker-specific optimizations that range widely depending on market regimes. This resource allows users to explore data-driven approaches tailored to individual preferences. Explore the full collection on the Trending AI Robots page for detailed statistics and deployment options.
Head-to-Head Comparison
In business model terms, TMO operates as a larger, more diversified platform spanning multiple scientific verticals, while BIO maintains a focused presence in core research and diagnostics instrumentation. Growth drivers differ accordingly: TMO benefits from scale in recurring revenue streams and global reach, whereas BIO contends with concentrated exposure to research budgets. Recent momentum favors TMO through steadier top-line expansion, contrasting with BIO’s guidance adjustments amid external spending pressures. Risk factors include BIO’s sensitivity to investment mark-to-market swings and sector-specific funding cuts, versus TMO’s broader but still cyclical exposure to capital equipment cycles. Market sentiment in recent weeks reflects these contrasts, with TMO viewed for relative stability and BIO for potential niche recovery opportunities.
Tickeron AI Verdict
Based on observable factors such as trend consistency, scale-driven stability, and relative positioning within the sector, Tickeron’s AI would currently assign a higher probabilistic preference to TMO. Its demonstrated ability to sustain organic growth and broader market access provide a more resilient profile in the prevailing environment compared to BIO’s narrower focus and recent guidance revisions. This assessment remains probabilistic and subject to evolving data rather than a definitive recommendation.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIO is a StrongBuy and TMO is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BIO’s FA Score shows that 1 FA rating(s) are green whileTMO’s FA Score has 1 green FA rating(s).
- BIO’s FA Score: 1 green, 4 red.
- TMO’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BIO’s TA Score shows that 4 TA indicator(s) are bullish while TMO’s TA Score has 6 bullish TA indicator(s).
- BIO’s TA Score: 4 bullish, 4 bearish.
- TMO’s TA Score: 6 bullish, 4 bearish.
Price Growth
BIO (@Medical/Nursing Services) experienced а +0.82% price change this week, while TMO (@Medical Specialties) price change was +2.11% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +7.62%. For the same industry, the average monthly price growth was -1.16%, and the average quarterly price growth was -16.57%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -3.19%. For the same industry, the average monthly price growth was +9.26%, and the average quarterly price growth was +1.11%.
Reported Earning Dates
BIO is expected to report earnings on Jul 30, 2026.
TMO is expected to report earnings on Jul 23, 2026.
Industries' Descriptions
@Medical/Nursing Services (+7.62% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (-3.19% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| BIO | TMO | BIO / TMO | |
| Capitalization | 8.02B | 196B | 4% |
| EBITDA | 440M | 11.7B | 4% |
| Gain YTD | -1.786 | -8.609 | 21% |
| P/E Ratio | 49.51 | 29.05 | 170% |
| Revenue | 2.59B | 45.2B | 6% |
| Total Cash | 1.57B | 1.12B | 140% |
| Total Debt | 1.38B | 43.2B | 3% |
BIO | TMO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 59 | 23 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 83 Overvalued | 13 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 83 | |
SMR RATING 1..100 | 90 | 62 | |
PRICE GROWTH RATING 1..100 | 52 | 48 | |
P/E GROWTH RATING 1..100 | 10 | 34 | |
SEASONALITY SCORE 1..100 | 90 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TMO's Valuation (13) in the Medical Specialties industry is significantly better than the same rating for BIO (83). This means that TMO’s stock grew significantly faster than BIO’s over the last 12 months.
TMO's Profit vs Risk Rating (83) in the Medical Specialties industry is in the same range as BIO (100). This means that TMO’s stock grew similarly to BIO’s over the last 12 months.
TMO's SMR Rating (62) in the Medical Specialties industry is in the same range as BIO (90). This means that TMO’s stock grew similarly to BIO’s over the last 12 months.
TMO's Price Growth Rating (48) in the Medical Specialties industry is in the same range as BIO (52). This means that TMO’s stock grew similarly to BIO’s over the last 12 months.
BIO's P/E Growth Rating (10) in the Medical Specialties industry is in the same range as TMO (34). This means that BIO’s stock grew similarly to TMO’s over the last 12 months.
| BIO | TMO | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 55% |
| Stochastic ODDS (%) | 1 day ago 75% | 1 day ago 58% |
| Momentum ODDS (%) | 1 day ago 73% | 1 day ago 64% |
| MACD ODDS (%) | 1 day ago 60% | 1 day ago 63% |
| TrendWeek ODDS (%) | 1 day ago 66% | 1 day ago 61% |
| TrendMonth ODDS (%) | 1 day ago 66% | 1 day ago 61% |
| Advances ODDS (%) | 18 days ago 66% | 1 day ago 61% |
| Declines ODDS (%) | 6 days ago 68% | 6 days ago 63% |
| BollingerBands ODDS (%) | 1 day ago 65% | 1 day ago 56% |
| Aroon ODDS (%) | 1 day ago 78% | 1 day ago 56% |
Advertisement
BIO and
Correlation & Price change
A.I.dvisor indicates that over the last year, BIO has been closely correlated with A. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if BIO jumps, then A could also see price increases.